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ABSTRACT: We examined the frequency of Par-
kinson disease with mild cognitive impairment (PD-MCI)
and its subtypes and the accuracy of 3 cognitive scales for
detecting PD-MCI using the new criteria for PD-MCI pro-
posed by the Movement Disorders Society. Nondemented
patients with Parkinson’s disease completed a clinical visit
with the 3 screening tests followed 1 to 3 weeks later by
neuropsychological testing. Of 139 patients, 46 met Level
2 Task Force criteria for PD-MCI when impaired perform-
ance was based on comparisons with normative scores.
Forty-two patients (93%) had multi-domain MCI. At the
lowest cutoff levels that provided at least 80% sensitivity,
specificity was 44% for the Montreal Cognitive Assess-
ment and 33% for the Scales for Outcomes in Parkinson’s
Disease-Cognition. The Mini-Mental State Examination
could not achieve 80% sensitivity at any cutoff score. At
the highest cutoff levels that provided specificity of at least
80%, sensitivities were low (44%) for all tests. When
decline from estimated premorbid levels was considered
evidence of cognitive impairment, 110 of 139 patients were
classified with PD-MCI, and 103 (94%) had multi-domain
MCI. We observed dramatic differences in the proportion
of patients who had PD-MCI using the new Level 2 criteria,
depending on whether or not decline from premorbid level
of intellectual function was considered. Recommendations
for methods of operationalizing decline from premorbid lev-
els constitute an unmet need. Among the 3 screening tests
examined, none of the instruments provided good com-
bined sensitivity and specificity for PD-MCI. Other tests
recommended by the Task Force Level 1 criteria may rep-
resent better choices, and these should be the subject of
future research. VC 2013 Movement Disorder Society
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Mild cognitive impairment (MCI) is being recog-
nized increasingly at all stages of Parkinson’s disease
(PD). In order to facilitate research in PD-MCI and,
ultimately, to guide clinical care, methods that accu-
rately detect individuals with PD-MCI are required.
Criteria for diagnosing PD-MCI and defining subtypes
have varied across studies. Recently, new criteria were
published by the Movement Disorders Society (MDS)
Task Force on PD-MCI.1 These criteria provide meth-
ods for diagnosing PD-MCI using either an abbrevi-
ated assessment (Level 1 criteria) or a comprehensive
assessment (Level 2 criteria). The Level 1 criteria
suggest using a limited neuropsychological test
battery or any of several multidimensional scales of
cognitive abilities (the Montreal Cognitive Assessment
[www.mocatest.org], the Parkinson’s Disease Cogni-
tive Rating Scale [PD-CRS2], the Scales for Outcomes
in Parkinson’s Disease-Cognition [SCOPA-Cog]
[http://www.scopa-propark.eu/]. or the Mattis Demen-
tia Rating Scale [MDRS3]). The Level 2 criteria specify
how to make use of a more extensive neuropsycholog-
ical test battery to make the diagnosis. In this study,
we examine the frequency of PD-MCI and its subtypes
according to the Level 2 criteria and several varia-
tions. We also assess the diagnostic accuracy of the
Montreal Cognitive Assessment, the Mini-Mental
State Examination (MMSE), and the SCOPA-Cog for
detecting PD-MCI using the Level 2 criteria as a gold
standard. Two prior studies have assessed the ability
of the MoCA, MMSE, and/or SCOPA-Cog to detect
PD-MCI4; however, to our knowledge, there are no




Nondemented PD patients were enrolled at 6 North
American movement disorders centers. Recruitment
started in December 2008 and continued through June
2011. Inclusion criteria were a diagnosis of PD
according to the United Kingdom PD Society Brain
Bank criteria,6 age 60 years, English as first lan-
guage, grade 8 or higher education, and a standard
score of at least 80 on the Wechsler Test of Adult
Reading (WTAR) (The Psychological Corporation,
San Antonio, TX), a standardized estimate of premor-
bid IQ. Exclusion criteria were evidence of impair-
ments in activities of daily living or instrumental
activities of daily living related to cognition on the
modified Disability Assessment for Dementia (DAD),
neuropsychological testing within the past year, a
score 5 or greater on the 15-item Geriatric Depression
Scale (GDS), currently unstable psychiatric disorder,
and prior or planned neurosurgical intervention (eg
deep brain stimulation). Enrolled patients received a
clinical evaluation followed 1 to 3 weeks later by for-
mal neuropsychological testing performed by exam-
iners blinded to clinical results.
Each participating institution received local ethics
approval before study enrolment. Written informed
consent was obtained from all study participants and
participating informed contacts (defined as contact at
least twice weekly) before formal screening and study
visits.
Clinical Assessment
The clinical evaluation included the MoCA, the
MMSE, the SCOPA-Cog, the Neurobehavioral Signs
and Symptoms Abbreviated Inventory (NBI) (Profes-
sional Resources and Technologies, Westtown, PA; a
list of 19 cognitively based problems with everyday
life), and the MDS Unified Parkinson’s Disease Rating
Scale (MDS-UPDRS). Given overlapping items, the
order of administration of the MoCA and the MMSE
were alternated to avoid bias in performance related
to fatigue, learning, or other effects related to order.
All investigators were trained in administering these
tests and followed a standard protocol. A consenting
informed contact completed the NBI and a modified
version of the DAD in reference to the participant.
The modified DAD added a question regarding
whether any reported impairment was related to cog-
nitive difficulties or the physical impairments of PD.
Neuropsychological Testing
Neuropsychological testing was performed 1 to 3
weeks after the clinical evaluation to balance the
risks of changes in the intervening time and potential
interference from similar tasks on clinical and neuro-
psychological evaluations. Different individuals admin-
istered the clinical evaluation and neuropsychological
testing. Two neuropsychological tests were designated
to represent each of 5 the following cognitive domains
on the basis of having as little reliance as possible on
other cognitive domains: attention was tested with the
Wechsler Memory Scale-III (WMS-III) letter-number
sequencing test7 and the Delis Kaplan Executive Func-
tion System (DKEFS) Color Word Interference Color
Naming test,8 language was tested with the 30-item
Boston Naming Test9 and the DKEFS Verbal Fluency
Category Fluency test,8 visuospatial function was
tested with the Benton Judgment of Line Orientation
(JLO) test10 and the Copy Trial of the Rey Complex
Figure Test and Recognition Trial (RCFT),11 memory
was tested using the RCFT Delayed Recall and the
California Verbal Learning Test-II (CVLT-II) Long
Delay Free Recall test,12 and executive function
was tested using the Visual Verbal Test abbreviated
10-item version13 and the Trail Making Test B minus
A.14 The Trail Making Test is corrected for education;
the other tests have no correction for education and,
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thus, none was applied. Clinical and neuopsychologi-
cal evaluations were performed at a similar time of
day and participants were evaluated in the ON state
as judged by the patient’s self-report of the effective-
ness of their PD medication at the time of testing.
Diagnosis of PD-MCI
Primary criteria for PD-MCI were based on MDS
Task Force criteria for PD-MCI Level 2 criteria (com-
prehensive assessment) and required (1) a cognitive
complaint from the patient or informed contact consist-
ing of 1 or more items endorsed on the NBI, (2) no
functions impaired because of cognition as assessed by
the modified DAD, and (3) impaired performance on at
least 2 of the 10 neuropsychological tests. Impaired per-
formance on a neuropsychological test was defined pri-
marily as a score that was at least 1.5 standard
deviations (SDs) below the age-adjusted mean from nor-
mative samples. The Task Force criteria also recom-
mend incorporating information on decline from
premorbid level using the WTAR or a similar test when
available. We calculated decline from premorbid level
as the difference between the patient’s age/ethnicity/edu-
cation-specific WTAR full scale IQ z-score and their
neuropsychological test z-score. If the neuropsychologi-
cal test z-score was less than the WTAR full scale IQ z-
score by greater than 1.5, then the neuropsychological
test performance was considered impaired. Because the
Task Force did not provide any guidelines for use of the
WTAR or similar tests of premorbid intellectual func-
tioning, we report the results incorporating this aspect
as a secondary analysis. Considering that impairment of
insight may in fact be an integral feature of PD-MCI
for some patients, we also varied the primary criteria by
eliminating the need for a cognitive complaint.
The criteria for PD-MCI were applied at a consen-
sus conference that included a neuropsychologist and
2 neurologists. Individuals who met cognitive criteria
for MCI but were deemed to have functional impair-
ment related to cognition (1 or more items on the
DAD impaired due to cognition) were classified as
having dementia. The medication lists were reviewed
for medications with the potential to impair cognition,
and a subjective determination was made regarding
whether or not the doses, frequency, and combination
of medications were likely to impair cognition.
We also assigned subtypes of MCI according to the
Task Force criteria.1 An individual was designated as
having single-domain PD-MCI if 2 tests from only 1
cognitive domain were impaired. Multi-domain
PD-MCI was assigned if at least 1 test from 2 or more
domains was impaired.
Statistical Analysis
Nonparametric Wilcoxon rank-sum tests were used
to compare continuous measures across groups
according to PD-MCI status. The v2 test was used to
compare proportions. Individuals were classified as
having PD-MCI or not. Sensitivity, specificity, and
positive and negative predictive values of the MoCA,
MMSE, and SCOPA-Cog were calculated across all
possible cutoff scores below which an individual
would be classified as having PD-MCI. The area under
the receiver-operator characteristics curve (AUC) was
calculated and compared across the 3 tests. AUC con-
fidence intervals (CIs) were generated according to the
methods of Delong et al.15 Differences in estimated
AUCs were assessed using bootstrap methodologies
(2000 bootstrap replicates) implemented using the R
library pROC (R Foundation for Statistical Comput-
ing, Vienna, Austria).16 The test statistic of interest for
pairwise comparison of AUCs is D 5 (AUC1 2 AUC2)/
SD(AUC1 2 AUC2). The observed value of D was
compared with that of a standard normal distribution.
Permutation tests were used to compare specificities at
a given sensitivity threshold, and vice versa. Logistic
generalized estimation equation (GEE) models were
used to assess differences in the probability of correct
classification between tests within MCI subtypes. A
compound symmetry working correlation structure
was assumed for the GEE model. The inference was
robust to the choice of working correlation structure.
Results
We recruited 139 patients from an initial screening of
169 and excluded 30 for the following reasons: impair-
ment in function because of cognitive impairment (ie,
dementia; n 5 6), withdrawal of consent (n 5 4), posi-
tive screen for depression (n 5 4), did not meet UK
Brain Bank criteria for PD (n 5 4), non-native English
speaker (n 5 4), prior head injury (n 5 2), educational
attainment less than grade 8 (n 5 1), recent neuropsy-
chological testing (n 5 1), color blindness (n 5 1), age
<60 years (n5 1), and unrecorded reasons (n 5 2).
According to our primary MDS Task Force Level 2 cri-
teria, 46 individuals (33%) were classified as having
PD-MCI. Table 1 lists the clinical features of the
patients overall and by PD-MCI classification according
to those criteria. The groups had similar disease dura-
tion, severity, educational level, and age.
Table 2 lists the frequencies of PD-MCI and its sub-
types according to the different sets of criteria applied.
When we included decline from estimated premorbid
levels, the proportion of the cohort classified with PD-
MCI rose from 33% to 79%. Eliminating the need for
a cognitive complaint increased the proportion classi-
fied with PD-MCI by a small amount (to 41%).
According to the primary criteria, 43 patients (93%)
were classified with multi-domain MCI. Of those
patients who had multi-domain PD-MCI, 36 of 43
(84%) had impairments in 1 or both executive tasks,
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34 of 43 (79%) had impairments in 1 or both visuo-
spatial tasks, 20 of 43 (47%) had impairments in 1 or
both memory tasks, 11 of 43 (26%) had impairments
in 1 or both attention tasks, and 8 of 43 (19%) had
impairments in 1 or both language tasks. Because of
the preponderance of multi-domain PD-MCI, we
explored 1 additional variation of PD-MCI criteria:
requiring 2 tests within a domain to be greater than
1.5 SD below the normative mean to declare impair-
ment on a domain and requiring impairment in at
least 1 domain to qualify as PD-MCI. According to
this method, the proportion of individuals classified
with PD-MCI declined to 22%, and a much higher
proportion of patients with PD-MCI had single-do-
main MCI than when MDS Task Force Level 2 crite-
ria were used (77% vs 7%). Almost equal numbers of
individuals were assigned as having visuospatial sin-
gle-domain PD-MCI (n 5 11) and executive single-do-
main PD-MCI (n 5 11). Two patients had single-
domain learning/memory PD-MCI.
Performance of the MoCA, MMSE, and
SCOPA-Cog
Table 3 shows the performance of the 3 tests for
detecting PD-MCI across different cutoff scores using
the primary criteria. The receiver-operator characteris-
tics curves are illustrated in Figure 1. The AUC was
0.71 (95% CI, 0.60–0.80) for the MoCA, 0.68 (95%
CI, 0.58–0.78) for the MMSE, and 0.72 (95% CI,
0.62–0.81) for the SCOPA-Cog. None of the pair-wise
comparisons testing for a non-zero difference in AUC
estimates were statistically significant.
Screening Cutoff Scores
No cutoff score on the MMSE provided 80%
sensitivity. At the lowest cutoff score that provided
80% sensitivity, the specificity of the MoCA (at 26 or
less; ie, classifying individuals who scored 26 or less as
having PD-MCI) was 44%, and the specificity of the
SCOPA-Cog (at 30 or less) was 33% (P 5 0.26 for the
difference in specificity). Diagnostic accuracy (the per-
centage diagnosed correctly) at these cutoff scores was
57% for the MoCA and 50% for the SCOPA-Cog.
Diagnostic Cutoff Scores
The highest cutoff scores that provided at least 80%
specificity were 23 or less (ie, classifying individuals
who scored 23 or less as having PD-MCI) for the
MoCA, 26 or less for the MMSE, and 24 or less for the
SCOPA-Cog. These cutoff scores provided sensitivity
ranging from 35% to 44% and diagnostic accuracy
ranging from 68% to 73%. The sensitivities of the 3
tests did not differ significantly at these cutoff values.
MDS Task Force Level 2 Criteria Considering
Premorbid Intellectual Function
Supplemental Table 1 illustrates the performance of
the 3 tests when decline from estimated premorbid
TABLE 1. Characteristics of patients by modified Petersen Parkinson’s disease with mild cognitive impairment diagnosis
Mean 6 SD
Characteristic Total No PD-MCI PD-MCI Pa
Total no. 139 93 46 —
Age, y 71.1 (65.4) 71.1 (65.7) 71.16 4.8 0.87
Sex, % men 67% 69% 63% 0.50
Education, y 15.826 2.48 16.16 2.4 15.36 2.7 0.08
Time since diagnosis, y 5.236 4.64 5.06 4.0 5.86 5.8 0.73
Total MDS-UPDRS 43.196 16.83 42.56 16.7 44.76 17.1 0.42
MDS-UPDRS-III 26.846 11.27 26.76 11.7 27.26 10.4 0.55
Total LEU, mg 5616 419 5576 447 5696 359 0.56
Cognitive enhancing medications 6 2 4 0.09
Potentially cognitive impairing medications 5 2 3 0.33
Opiate 2 1 1 1.00
Hypnoticb 17 11 6 1.00
Antipsychotic 0 0 0 1.00
Anticholinergicc 21 14 7 1.00
Estimated premorbid IQ 113.26 9.0 114.86 8.2 109.9 (69.8) 0.002
MoCA 25.26 2.9 25.96 2.4 23.86 3.3 <0.0001
SCOPA-Cog 27.516 4.84 28.86 3.9 24.96 5.5 <0.0001
MMSE 28.146 1.98 28.66 1.5 27.16 2.5 0.0006
aAll P values were calculated using the Wilcoxon rank-sum test except sex, for which the v2 test was used.
bThese included benzodiazepines, zopiclone, and zaleplon.
cThese included trihexyphenidyl, ethopropazine, tolterodine, oxybutinin, amitriptyline, and solifenacin.
SD, standard deviation; MCI, mild cognitive impairment; MDS-UPDRS-III, Movement Disorders Society United Parkinson’s Disease Rating Scale, part 3; LEU,
levodopa equivalent units; MoCA, Montreal Cognitive Assessment; SCOPA-Cog, Scale for Outcomes in Parkinson’s Disease-Cognition; MMSE, Mini-Mental
State Examination.
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ability was included in the assessment. Once again, the
MMSE was unable to achieve 80% sensitivity at any
cutoff score. At optimal screening cutoff scores (the
lowest score providing sensitivity of at least 80%), the
specificities of the MoCA and SCOPA-Cog were both
17%. At optimal diagnostic cutoff scores (the highest
score providing specificity of at least 80%), the sensitiv-
ities of the MoCA, MMSE, and SCOPA-Cog ranged
from 22% to 35%. The sensitivities of the 3 tests were
not significantly different at these cutoff values.
Discussion
The MDS Task Force criteria for PD-MCI resulted in
a similar proportion of patients being classified with PD-
MCI compared with previous reports in which impaired
performance was determined based on comparisons with
normative scores. When a decline from the estimated pre-
morbid level was considered evidence of cognitive
impairment (as suggested by the MDS Task Force), a
much higher proportion of the cohort was classified with
PD-MCI than in previous studies, which have reported a
frequency of PD-MCI usually in the range of 19% to
25%4,5,17,18 and as high as 53%.19 Cognitive decline
from premorbid levels may be important for patients
whose expectations are based on their levels of premor-
bid functioning. For example, for an individual who is
gainfully employed, even a slight decline might result in
inability to continue at their customary job. It would be
important to learn which classification approach (with





PD-MCI: No. (% of MCI)
Multi-domain PD-MCI:
No. (% of MCI)
1. MDS Task Force level 2 defining impairment based on
comparisons to normative scores
46 (33) 3 (7) 43 (93)
2. MDS Task Force level 2 including decline from premorbid level 110 (79) 7 (6) 103 (94)
3. As in 1 and disregarding cognitive complainta 57 (41) 5 (9) 52 (91)
4. As in 1 and requiring 2 tests abnormal per domainb 31 (22) 24 (77)c 6 (19)d
aThis requires neuropsychological test scores 1.5 standard deviations (SD) below the normative mean to qualify as impaired (regardless of premorbid level)
and disregarding the presence or absence of a cognitive complaint.
bThis requires neuropsychological test scores 1.5 SD below the normative mean to qualify as impaired (regardless of premorbid level) and requires 2 tests within
a domain to be 1.5 SD below the normative mean to declare impairment on a domain. Impairment in at least 1 domain is required to qualify as PD-MCI.
cVisuospatial MCI, 11; executive MCI, 11; learning/memory MCI, 2.
dUnable to classify 1 patient because of 1 missing neuropsychological test value.
PD-MCI, Parkinson’s disease with mild cognitive impairment; MDS, Movement Disorder Society.
TABLE 3. Performance characteristics of the cognitive screening instruments for detecting Parkinson’s disease with mild
cognitive impairment according to Movement Disorders Society Task Force level 2 criteria across a range of possible
cutoff scoresa
Cutoff scoreb
Screening instrument 23/24 24/25 25/26 26/27 27/28 28/29 29/30 30/31 31/32 32/33 33/34
MoCA
Sensitivity 0.413 0.522 0.674 0.826 0.87 0.913 0.957
Specificity 0.817 0.785 0.624 0.441 0.301 0.151 0.022
PPV 0.528 0.545 0.47 0.422 0.381 0.347 0.326
NPV 0.738 0.768 0.795 0.834 0.824 0.778 0.5
% Correctly diagnosed 0.683 0.698 0.64 0.568 0.489 0.403 0.331
MMSE
Sensitivity 0.152 0.133 0.348 0.5 0.673 0.783
Specificity 0.989 0.941 0.914 0.785 0.667 0.355
PPV 0.875 0.875 0.667 0.535 0.547 0.375
NPV 0.702 0.26 0.739 0.76 0.773 0.767
% Correctly diagnosed 0.712 0.755 0.727 0.691 0.626 0.496
SCOPA-Cog
Sensitivity 0.435 0.522 0.652 0.717 0.739 0.783 0.848 0.87 0.913 0.913
Specificity 0.878 0.774 0.71 0.624 0.462 0.719 0.333 0.28 0.183 0.14
PPV 0.625 0.533 0.526 0.485 0.405 0.4 0.386 0.374 0.356 0.344
NPV 0.768 0.766 0.805 0.817 0.782 0.796 0.816 0.813 0.81 0.765
% Correctly diagnosed 0.727 0.691 0.691 0.655 0.554 0.54 0.504 0.475 0.424 0.396
aThe scores disregarding premorbid ability are listed.
bThe maximum possible scores are 30 for the MoCA, 30 for the MMSE, and 43 for the SCOPA-Cog.
MoCA, Montreal Cognitive Assessment; PPV, positive predictive value; NPV, negative predictive value; MMSE, Mini-Mental State Examination; SCOPA-Cog,
Scale for Outcomes in Parkinson’s Disease-Cognition.
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our without considering premorbid cognitive function)
results in a more meaningful separation of patients on
the basis of both quality of life and prognosis.
It is rare that a patient comes to evaluation with prior
neuropsychological testing that would provide an undis-
puted baseline. Thus, clinicians rely heavily on history
(level of education, occupation, hobbies) and current
test scores on measures resistant to neurological insult,
such as the WTAR, that can yield an estimate of pre-
morbid function. A gap in the MDS Task Force criteria
for PD-MCI is guidance on how to determine an impor-
tant decline using such measures, particularly for
research purposes, where a reproducible method is de-
sirable. In strict application to identify loss of function,
the WTAR manual recommends comparing predicted
Wechsler Adult Intelligence Scale (WAIS)-III IQ scores
and Wechsler Memory Scale (WMS)-III scores with a
patient’s current performance (eg WTAR-demographic
predicted full-scale IQ). However, use of the WAIS-III
and WMS-III test batteries in a PD cognitive research
setting is impractical because of long administration
times; and, more important, the sensitivity of these
global index scores from the WAIS scales is poor for
detecting early cognitive changes in association with
PD.20,21 Therefore, an alternative method of defining
decline using these premorbid estimates is needed.
In the absence of WAIS-III or WMS-III scores,
we operationalized decline at 1.5 SD from the
WTAR-demographic estimated full-scale IQ and
applied this across the domains represented by our
chosen core neuropsychological tests. We recognize
that this operationalization has its limitations. WTAR
scores correlate highly with full-scale IQ and verbal
IQ but to a lesser degree with other domains, and the
95% CIs of WTAR-predicted IQ scores are large.
However, in patients with high premorbid functioning
like those in our cohort, WTAR-predicted scores will
tend to underestimate the amount of cognitive deterio-
ration that has occurred. A 1.5-SD criterion for
decline is also conservative relative to the definitions
of decline based on the WAIS-III and WMS-III. For
these reasons, we believe that the 79% PD-MCI we
observed in our sample is likely an underestimate of
the proportion of individuals who have actually expe-
rienced a decline from premorbid cognitive function.
The MDS Task Force Level 2 criteria also suggest that
decline on serial neuropsychological testing should be
used as a criterion for impairment on neuropsycholog-
ical tests. We did not have any prior neuropsychologi-
cal testing on these individuals to apply this criterion.
Incorporating this aspect could result in an even
higher proportion of the cohort classified with PD-
MCI according to the new criteria.
When we examined the subtype of PD-MCI in our
sample using the MDS Task Force criteria, the vast
majority of patients were classified with multi-domain
FIG. 1. Receiver-operator characteristic (ROC) curves for the 3 cognitive screening tests are illustrated.
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MCI (93%). Using various definitions, prior studies
have reported that multi-domain PD-MCI comprised
as low as 14% and as high as 61% of the PD-MCI
cases in their samples.17–19,22–25 The high proportion
of multi-domain MCI in our sample appears to reflect
the new MDS Task Force criteria, in that a multi-do-
main MCI designation only requires 1 abnormal test
in each domain in contrast to single-domain MCI,
which requires 2 abnormal tests within the affected
domain. Other studies have approached this differ-
ently, requiring the same number of abnormal tests
per domain or the same degree of abnormality per
domain regardless of whether a single or multiple
domains are affected.17–19,23,24 When we modified
the MDS Task Force criteria to require 2 abnormal
tests per domain regardless of single-domain or
multi-domain designation, the subtype distribution
shifted such that the majority of patients were classi-
fied with single-domain MCI, and designation of the
predominantly affected domains was clear. By using
this method, executive and visuospatial functions were
the most commonly affected domains in our cohort, in
line with several other reports.18,19,23
The performances of the MoCA, MMSE, and
SCOPA-Cog were poor when using MDS Task Force
criteria whether or not premorbid ability was consid-
ered to define cognitive decline. For neither definition
of PD-MCI could any of these tests achieve a desirable
combined sensitivity and specificity. This calls into
question the recommendation of the Task Force,
which suggests that either the MoCA or the SCOPA-
Cog can be used to diagnose possible PD-MCI (Level
1 criteria). Other studies that have examined 1 or
more of these tests for the purpose of identifying indi-
viduals with PD-MCI4,5 have concluded that the
MoCA performs reasonably well for this purpose and
somewhat better than the other tests. In those studies,
MoCA cutoff scores that provided sensitivities and
negative predictive values above 80% (designated the
optimal screening cutoff score) were 25 or less4 and
26 or less.5 At these cutoff scores, specificities ranged
from 52% to 75%. The sensitivities of the MMSE
and/or SCOPA-Cog generally were lower than for the
MoCA in those studies.
The desired characteristics of a diagnostic test depend
on the purpose for which it will be used. Currently, PD-
MCI does not have specific treatment implications,
although ongoing work in this important issue will
likely lead to further studies. There has been 1 report
from a randomized trial of rasagiline demonstrating
positive effects on cognitive tests in PD patients without
dementia,26 but no studies have specifically examined
patients with MCI. Although a few studies have suggest
that PD-MCI has prognostic implications (for a useful
review, see Litvan et al.27), currently, the need to iden-
tify patients with PD-MCI is largely for the purpose of
enrolment in research studies. For this purpose, a test of
high specificity is desired to ensure that the popula-
tion of interest is being studied and to allow mean-
ingful interpretation of the results. High specificity
can be achieved using lower cutoff scores but with
low sensitivity for all 3 tests, which would result in
questionable generalizability of any cohort recruited
in this way. The MDS Task Force Level 1 criteria
also suggest that the PD-CRS and the MDRS are
useful tools for diagnosing PD-MCI using an abbrevi-
ated assessment. Assessing the performance of those
instruments using the new Level 2 criteria as a gold
standard would be a useful next step.
Conclusions
Our exploration of the new MDS Task Force crite-
ria for PD-MCI leads to 2 important observations.
First, the proportion of individuals classified as having
PD-MCI is much higher than in previous reports when
incorporating a decline from estimated premorbid lev-
els into the definitions of impairment, as the Task
Force suggests. Whether or not this is appropriate
depends on whether or not the new method results in
a more meaningful separation of groups on the basis
of characteristics like quality of life or prognosis. This
should be the subject of future study, as should meth-
ods for operationalizing the definition of decline using
the WTAR or other estimates of premorbid function.
Second, the vast majority of PD-MCI is classified as
multi-domain MCI by the new criteria. A minor alter-
ation of the criteria results in a separation of subtypes
that may be more useful for research purposes.
We did not find meaningful differences in per-
formance between the MoCA, MMSE, or SCOPA-
Cog as a screening or diagnostic tool for PD-MCI.
Our results indicate that, to recruit a representative
cohort of patients with PD-MCI for research pur-
poses, none of the tests studied would be adequate
alone, and any would need to be followed by a
second test with higher specificity. Future research
should identify a follow-up test that, together with
the screen, can constitute an efficient way to iden-
tify individuals with PD-MCI. Furthermore, these
findings call for a reconsideration of the MDS Task
Force Level 1 criteria, which suggest that either the
MoCA or the SCOPA-Cog may be used as a brief
test for PD-MCI.
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